Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome

Clinical trial NCT03094637 · UNKNOWN

Trial details

NCT number: NCT03094637
Sponsor: M.D. Anderson Cancer Center
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

High Risk Myelodysplastic Syndrome IPSS Risk Category Intermediate-1 Myelodysplastic Syndrome

Start date: 2017-11-06
Primary completion: 2021-11-06
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.